Related Experiment Video
Updated: May 12, 2026

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
Published on: April 11, 2025
Evaluation of new vectorcardiography algorithms for identifying left ventricular hypertrophy and impaired systolic
Janek Salatzki1, Arne Kristian Schwarz2, Sarah Wolfsteller3
1Department of Cardiology, Angiology and Pneumology, Heidelberg University Hospital, 69120 Heidelberg, Germany; William Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.
Insights
Vectorcardiography (VCG) effectively screens for impaired systolic function and left ventricular hypertrophy (LVH), offering a scalable alternative to advanced imaging. This method shows high accuracy, aiding early diagnosis of structural heart disease.
Area of Science:
- Cardiology
- Medical Imaging
- Artificial Intelligence
Background:
- Diagnosing impaired systolic function and left ventricular hypertrophy (LVH) is challenging.
- Electrocardiography has limited accuracy for subtle cardiac abnormalities.
- Vectorcardiography (VCG) offers a potential solution for screening structural heart disease.
Purpose of the Study:
- To assess the diagnostic performance of VCG for identifying impaired systolic function and LVH.
- To compare VCG findings with cardiac magnetic resonance imaging (CMR) results.
Main Methods:
- A prospective case-control study involved 245 participants.
- Participants underwent both CMR and VCG.
- An AI algorithm analyzed 583 VCG parameters.
Main Results:
- VCG parameters demonstrated high diagnostic accuracy for impaired systolic function (AUC 0.843) and LVH (AUCs 0.739-0.791).
- Overall diagnostic accuracy reached 81.7% for systolic dysfunction and 78.2% for LVH.
- The combined phenotype was detected with 83.1% accuracy.
Conclusions:
- VCG reliably detects left ventricular systolic dysfunction and hypertrophy.
- VCG serves as a scalable and interpretable screening tool, especially where advanced imaging is limited.
- Further multicenter studies are recommended for clinical validation.
Background:
Timely diagnosis of impaired systolic function and left ventricular hypertrophy (LVH) remains a clinical challenge. Routine electrocardiography provides limited diagnostic accuracy for detecting early or subtle structural abnormalities. Vectorcardiography (VCG), which captures the spatial and temporal characteristics of cardiac electrical activation and repolarization, may offer a rapid, scalable, and cost-effective alternative for screening structural heart disease.
Objective:
To evaluate the diagnostic performance of VCG for identifying impaired systolic function and left ventricular hypertrophy compared with cardiac magnetic resonance imaging.
Methods:
This prospective case-control study included 245 participants undergoing both CMR and VCG. Among 245 participants, 40 had reduced LVEF (<40%) and 208 met CMR criteria for LVH; 34 patients had both conditions. Patients were classified as having impaired systolic function (left ventricular ejection fraction [LVEF] <40%), LVH (indexed left ventricular mass ≥ 55 g/m2), or controls with structurally normal hearts. VCG was obtained using a five‑lead system (cardisiography), and signals were processed by an AI algorithm extracting 583 parameters. Diagnostic performance was evaluated using CMR as reference.
Results:
The repolarization time-difference ratio (Rpeak-Tonset / QRSend-Tpeak) showed the best diagnostic performance for impaired systolic function, with an area under the curve (AUC) of 0.843, sensitivity of 80.0%, and specificity of 83.9%. In LVH patients, three parameters-T-wave azimuth, T-wave magnitude, and azimuth variability-showed AUCs ranging from 0.739 to 0.791. Overall diagnostic accuracy was 81.7% for impaired systolic function and 78.2% for LVH, and 83.1% for the combined phenotype of reduced LVEF and LVH.
Conclusion:
VCG reliably detects left ventricular systolic dysfunction and hypertrophy. This approach offers a scalable and interpretable screening tool, especially valuable in settings with limited access to advanced cardiac imaging. Future multicenter studies are needed to validate these findings and support clinical implementation.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure IV: Classification and Diagnostic Evaluation
Acute Coronary Syndrome III: Diagnostic Studies
Cardiomyopathy V: Interprofessional Care
